Microbial production of virus-like particle vaccine protein at gram-per-litre levels
Autor: | Aravindan Rajendran, Anton P. J. Middelberg, Mervyn W.O. Liew |
---|---|
Rok vydání: | 2010 |
Předmět: |
Viral protein
Recombinant Fusion Proteins viruses Cell Count Bioengineering Biology medicine.disease_cause Applied Microbiology and Biotechnology Microbiology law.invention Bioreactors Microscopy Electron Transmission Virus-like particle law Escherichia coli medicine Bioreactor Biomass Vaccines Virus-Like Particle Cell Proliferation Glutathione Transferase virus diseases Murine polyomavirus General Medicine Hydrogen-Ion Concentration Fusion protein Fractionation Field Flow Capsid Recombinant DNA Capsid Proteins Electrophoresis Polyacrylamide Gel Biotechnology |
Zdroj: | Journal of Biotechnology. 150:224-231 |
ISSN: | 0168-1656 |
DOI: | 10.1016/j.jbiotec.2010.08.010 |
Popis: | This study demonstrates the feasibility of large-scale production of murine polyomavirus VP1 protein in recombinant Escherichia coli as pentamers which are able to subsequently self-assemble in vitro into virus-like particles (VLPs). High-cell-density pH-stat fed-batch cultivation was employed to produce glutathione-S-transferase (GST)-VP1 fusion protein in soluble form. The expression of recombinant VP1 was induced with IPTG at different cell optical densities (OD at 600 nm of 20, 60 or 100). GST-VP1 production was highest when the culture was induced at a cell density of OD 60, with volumetric yield reaching 4.38 g L −1 in 31 h, which we believe is the highest volumetric productivity for viral capsid protein reported to date. The induction cell density is shown to have a significant effect on the overall volumetric yield of recombinant VP1 and on final cell density, but not on VLP quality. VP1 yield was enhanced 15-fold by scaling-up from shake flask to pH-stat fed-batch cultivation in a bioreactor. Although numerous studies have expressed structural viral protein in E. coli , we believe this is the first report of translation to bioreactors yielding gram-per-litre levels. This VLP production technology overcomes major drawbacks associated with eukaryotic cell-based vaccine production technologies, and propounds the scope for large-scale commercially viable E. coli based VLP production by significantly reducing vaccine production time and cost. |
Databáze: | OpenAIRE |
Externí odkaz: |